Chembio Diagnostics to Report Third Quarter 2020 Financial Results on November 5, 2020
Chembio Diagnostics (CEMI) announced it will reveal its 2020 third-quarter financial results on November 5, 2020, after market close. A conference call with management is scheduled for 4:30 p.m. ET on the same day, where investors can participate via phone or online. Chembio focuses on point-of-care diagnostics for infectious diseases, utilizing its proprietary DPP technology for broad market applications. The company sells products globally to various healthcare organizations.
- Upcoming release of third-quarter financial results indicates transparency and ongoing business operations.
- Focus on point-of-care diagnostics positions Chembio favorably amid increasing demand for rapid testing.
- No specific financial metrics or guidance provided, leaving uncertainty about performance.
HAUPPAUGE, N.Y., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter 2020 after the close of trading on Thursday, November 5, 2020.
The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 844-602-0380 from the US or 862-298-0970 from outside the US or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US (using passcode 38202) or by accessing www.chembio.com/investors/calendar-of-events/.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.
| Investor contact: | |
| Philip Taylor Gilmartin Group (415) 937-5406 investor@chembio.com | |
FAQ
When will Chembio Diagnostics announce its third-quarter financial results for 2020?
What time is the Chembio Diagnostics conference call scheduled for?
How can I participate in the Chembio Diagnostics conference call?
What is Chembio Diagnostics' focus area?
What technology does Chembio Diagnostics use for its products?
